Breaking News, Collaborations & Alliances

Genezen Laboratories Receives Growth Equity Investment

Will fund the completion of the company’s lentiviral vector production facility.

By: Contract Pharma

Contract Pharma Staff

Genezen Laboratories Inc., a cell and gene therapy contract development and manufacturing organization (CDMO) focused on early-phase process development, vector production, and analytical testing services, has received a majority investment from Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector.   Ampersand’s investment will be used to complete the construction of the company’s 25,000 square foot cGMP-compliant lentiv...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters